Stocksigma LogoStocksigma Logo

Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization

CRISIL Ratings issued the Monitoring Agency Report for Solara Active Pharma Sciences for the quarter ended 30th Sep'26, confirming zero deviation in rights

Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization

Solara Active Pharma Sciences Ltd 路 Others (Uncategorized) 路 17 Oct 2026, 12:59 am

Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization CRISIL Ratings issued the Monitoring Agency Report for Solara Active Pharma Sciences for the quarter ended 30th Sep'26, confirming zero deviation in rights issue proceeds utilization. Out of the revised net proceeds of Rs 446.95 crore, the company has deployed Rs 439.88 crore, including Rs 334.71 crore fully utilized toward debt repayment and Rs 105.17 crore toward general corporate purposes. Unutilized funds stand at Rs 7.07 crore, comprising Rs 3.33 crore yet to be received from calls and Rs 3.74 crore held across monitoring and escrow accounts.

Original exchange filing (PDF)

More announcements from Solara Active Pharma Sciences Ltd

All Solara Active Pharma Sciences Ltd announcements